Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Too Much of a Good Thing
      • Turning Face Perception on Its Head
      • Safeguarding a Second Chance at Life
      • A Biological Betrayal
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
        • Earl Stadtman Investigator Frequently Asked Questions
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
The NIH Catalyst: A Publication About NIH Intramural Research

National Institutes of Health • Office of the Director | Volume 28 Issue 6 • November–December 2020

Resistance to the Plague May Be a Double-Edged Sword

The Bubonic Plague Has Made Its Evolutionary Mark on the Human Genome

BY ETHAN SMITH, NINR

Evolutionary pressure to survive the bubonic plague may have selected for genetic mutations that protect certain Mediterranean populations from being infected by the infamous Yersinia pestis, the bacterium behind the plague. But evolution isn’t perfect. Being able to survive the plague may also be the reason for today’s prevalence of another ancient disease—familial Mediterranean fever (FMF)—National Human Genome Research Institute (NHGRI) researchers recently reported in Nature Immunology (Nat Immunol 21:857–886, 2020).

Dan Kastner

Dan Kastner was a co-author of a study that found that genomic variants that cause familial Mediterranean fever may also confer increased resilience to the plague.

FMF, an autoinflammatory disease that mainly affects people of Mediterranean and Middle Eastern descent, is caused by mutations in the MEFV gene. The gene encodes pyrin, a protein involved in the inflammatory response. In healthy people, pyrin helps immune cells fight infection by increasing inflammation and producing inflammation-related molecules. In FMF patients, though, pyrin is activated without being triggered by an infection and can cause episodes of hyperinflammation: fever, chest pain, arthritis, and abdominal pain so bad it can be mistaken for appendicitis. Without treatment, FMF can lead to renal failure and death. People with two copies of the mutated MEFV gene are predisposed to FMF; those with only one copy of the mutated gene may develop FMF, but at a lower frequency.

But it turns out that having one or two copies of the mutated MEFV gene may be a secret weapon against the bubonic plague. Normally Y. pestis represses the function of pyrin in healthy individuals and in so doing suppresses the body’s inflammatory response to the plague. But the mutated MEFV genes prevent the ability of Y. pestis to interfere with the normal function of pyrin.

NHGRI Scientific Director Dan Kastner, a senior author on the paper, has studied FMF since 1985 when, as an NIH rheumatology fellow, he treated an Armenian patient who had the disease. Kastner’s group first considered that natural selection played a role in today’s prevalence of FMF because of its unusually high carrier frequency (proportion of people in a population who have only one copy of a mutant gene). The carrier frequency of MEFV mutations in Mediterranean populations is about 10%.

“It wasn’t just a high carrier frequency in one population,” said Kastner. “It was in Jewish populations, Arab, Turkish, [and] Armenian. It didn’t seem like something that would happen just by chance.” If chance were the only factor involved, the carrier frequency would be much lower.

four human figures, parent and three generations; DNA depiction

CREDIT: ERNESTO DEL AGUILA III, NHGRI

An illustration depicting specific genomic variants passed down to succeeding generations.

To provide evidence for natural selection, the researchers analyzed the genomes of 2,313 Turkish people and 352 ancient archeological samples including 261 from before the Christian era. Kastner’s team used mathematical modeling to estimate that two FMF-causing mutations in the MEFV gene arose more than 2,000 years ago. They also found that people with the same mutations had stretches of identical DNA flanking the mutation site. This set of DNA variants tends to be inherited together and is called a haplotype. According to evolutionary theory, if there is a selective pressure such as an infectious disease, a haplotype with mutations that protect humans in some way is conserved over the course of multiple generations. But if there is no selective pressure, the haplotype is no longer useful and is lost over time. In people with the normal MEFV gene, the researchers didn’t find a conserved haplotype.

But this evaluation was only evidence that natural selection was increasing the frequency of MEFV mutations in Mediterranean populations. The authors still had to figure out what was causing the natural selection.

Kastner’s group suspected Y. pestis as exerting a potential selective pressure on mutations in the pyrin gene because 1) Y. pestis releases a toxin called YopM that inactivates pyrin—it makes sense that humans would evolve a mutation in the pyrin gene that increases its resistance to YopM; 2) Y. pestis was an incredibly strong selective pressure—the bubonic plague wiped out a third of Europe’s population in the 14th century; and 3) Y. pestis has been able to shape the human genome for an incredibly long time—it was around during the 6th century Justinian plague and the 14th century Black Death.

The researchers found that, compared with cells from healthy control subjects, the immune cells isolated from the blood of people with FMF produced more interleukin 1-beta (an inflammation-causing protein) in response to Y. pestis infection. In addition, immune cells from people with only one copy of the mutated MEFV gene (and who usually do not develop FMF) were also resistant to Y. pestis infection. Even mice that were genetically altered to have two mutated MEFV genes had a clear survival advantage when infected with Y. pestis.

The findings demonstrate the double-edged sword that is evolution. “This is certainly not the first example of a mutation in a recessive disease gene being protective against an infectious agent…on the one hand…but on the other hand causing a human disease,” said Kastner.

Another example of a genetic mutation that is protective yet causes disease is the beta-globin gene, which when mutated causes sickle-cell anemia but also confers resistance to malaria.

Still, evolution has done what is best for humans. Despite a small number of people having two mutant MEFV copies and developing FMF, more have only one copy and are resistant to the bubonic plague.

Moving forward, Kastner plans to consider how interactions between hosts and microbes influence the evolution of other genetic diseases. “The host is just half of the equation, and there’s this whole other world, the microbial world,” said Kastner. “That’s the other half of the overall picture.”


Ethan Smith

Ethan Smith is a postbaccalaureate fellow in the National Institute of Nursing Research. He is working on clinical studies involving biomarkers for traumatic brain injury. When he completes his training in 2021, he expects to attend graduate school for social work. Outside of work he enjoys playing board games with friends, reading, and watching television.

This page was last updated on Monday, March 21, 2022

  • Issue Overview
  • Features
    • NHGRI Scientists Study Ancient Dog Breed
    • Resistance to the Plague May Be a Double-Edged Sword
    • Highlighting NIH’s Outstanding Women Fellows
    • COVID-19 Timeline at NIH (September–October 2020)
    • Joan Steitz’s WALS Lecture on Viral Noncoding RNAs
  • Departments
    • From the Deputy Director for Intramural Research
    • Alumni News: Andrea Pfeifer
    • Research Briefs
    • Colleagues: Recently Tenured
    • Announcements: Kudos
    • The Training Page
    • News You Can Use: Cyber Safety
    • The SIG Beat
    • News You Can Use: National Death Index
    • Technology Transfer: mHealth
    • From the Annals of NIH History
    • Photographic Moment
    • Announcements
  • Issue Contents
  • Download this issue as a PDF

Catalyst menu

  • Current Issue
  • Previous Issues
  • About The NIH Catalyst
  • Contact The NIH Catalyst
  • Share Your Story
  • NIH Abbreviations

Catalyst links

  • Follow The NIH Catalyst

Subscribe Today!

Subscribe to The NIH Catalyst Newsletter and receive email updates.

Subscribe

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search